Gallamine Triethiodide

CHEMBL1200993 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
891.5 g/mol
LogP
Phase
4

This neuromuscular blocking agent was historically used during surgery to relax skeletal muscles by competitively blocking acetylcholine at the neuromuscular junction. It has largely been replaced by newer agents with fewer cardiovascular side effects.

Peso molecular

891,5000 g/mol

TPSA

27,70 Ų

Mecanismo de acción

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]

InChI

InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3

Molecular Formula

C30H60I3N3O3

HBD / HBA

- / 6

Enlaces Rotables

21

Átomos Pesados

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This neuromuscular blocking agent was historically used during surgery to relax skeletal muscles by competitively blocking acetylcholine at the neuromuscular junction. It has largely been replaced by newer agents with fewer cardiovascular side effects.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Gallamine Triethiodide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200993. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6172. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.